AI models are rapidly improving – so fast that they may soon be able to develop themselves without human involvement. That’s ...

离职Meta后的田渊栋履新了。 2025年10月，Meta一刀裁掉了AI研究部门约600人，时任FAIR（基础AI研究团队）的研究科学家总监田渊栋也在其中。消息一出，OpenAI、Anthropic等头部AI公司纷纷向其抛出橄榄枝。但田渊栋没去任何一家，而是选择了创业。 美国当地时间5月13日，他以联合创始人身份现身Recursive Superintelligence（递归超级智能），在X平台宣 ...

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash ...

AI自我进化驱动底层范式转移。 一家创业公司获得了GV（Alphabet旗下VC）和Greycroft共同领投的6.5亿美元早期融资，NVIDIA和AMD也参与本轮融资，它的估值达到了46.5亿美元。 这家公司的创始人是Richard Socher，他是AI领域的顶尖研究者，也是连续创业者。在这一次创业前，他是You.com的创始人，也曾担任Salesforce的首席科学家。 除了他本人外，他还有 ...

Anthropic's internal data shows Claude writing most of its code, an early signal of recursive self-improvement in AI.

8月8日，两家AI制药龙头公司Recursion和Exscientia宣布已达成最终协议合并。Recursion是英伟达力挺的AI制药公司，致力于构建大型生物分子生成式AI模型，以实现药物发现的工业化；Exscientia则是更“传统意义”上的AI制药公司，利用高精度数据进行药物筛选、设计与开发。

In recent days, Recursion Pharmaceuticals reported positive early clinical data and advances in its AI-driven drug discovery pipeline, alongside a narrower-than-expected first-quarter EPS loss and ...

RSI is also defined as an “AI system capable of fully autonomously designing and developing its own successor,” per Anthropic’s blog post. “We are not there yet, and recursive self-improvement is not ...

Anthropic's research suggests AI is increasingly used to develop and improve new AI systems, with Claude now writing over 80% ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...